ImmunityBio, Inc. (IBRX)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow IBRX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on IBRX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
IBRX at a glance
Key statistics
$9.29B
Market capitalization
- Previous close
- $8.77
- Open
- $8.83
- Day range
- $8.33 – $8.98
- Volume
- 8.27M
- Average volume (30 sessions)
- 15.01M
- Shares outstanding
- 1.06B
- Earnings per share
- $(0.94)
- Price / sales
- 56.1
- Beta (1 year, vs SPY)
- 1.61
Where the price sits in its year
52-week range
64% of the range
- Below the 52-week high
- -30.5%
- Above the 52-week low
- +342.7%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $9.43-7.0%
- 50-day average
- $8.60+2.0%
- 200-day average
- $7.66+14.5%
Between the conventional 30 and 70 bands.
-10.5%
1 week
+3.8%
1 month
+16.8%
3 months
+342.9%
Year to date
+265.4%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with IBRX
IBRX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on IBRX.
See the plans →
Every planScreen names like IBRX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on IBRX
Put IBRX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on IBRX
See whether there is an open premium alert on IBRX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
IBRX headlines
- ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug
Benzinga · May 20, 2026
- ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies
Benzinga · May 19, 2026
- ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership
Benzinga · May 18, 2026
- IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman
GlobeNewswire Inc. · May 4, 2026
- IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
GlobeNewswire Inc. · May 1, 2026
SEC Form 4, most recent first
Insider filings
Simon Barry J.
−25.0K
Director · Open-market sale
$268.76K · Oct 5, 2026
Cohen Cheryl
−56.0K
Director · Option exercise
· Oct 2, 2026
Cohen Cheryl
+56.0K
Director · Option exercise
$166.82K · Oct 2, 2026
Cohen Cheryl
−81.1K
Director · Open-market sale
$851.09K · Oct 2, 2026
Selecky Christobel
−35.1K
Director · Option exercise
· Jul 1, 2026
Selecky Christobel
−124.4K
Director · Option exercise
· Jul 1, 2026
Cohen Cheryl
−131.2K
Director · Open-market sale
$1.25M · Jul 2, 2026
Cohen Cheryl
−56.0K
Director · Option exercise
· Jul 2, 2026
About ImmunityBio, Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- San Diego, CA
- Employees
- 691
- Listed since
- Mar 10, 2021
- Website
- immunitybio.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.